Media thread, page-138

1. Product invention ( discovery )
2. Capital Raise
3. Phase one Animal trials
4. Capital Raise
5. Phase two Human trials ( small trials )
6. Partnership
7. This is when Australian institution Investment start to catch on about Orthocell
8. Phase three Human trials ( larger trials ), USA
9. This is when International investment start to catch on about Orthocell
10. Commercialisation ( Royalties )
11. Revenue
12. NASDAQ second listing this is where J&J ( when successful after trials ) they will own 49% of the listing / partnership

The Australian market has not got a clue what any small biotech company could be worth, nationally and internationally, Management have been ticketing all the right boxes the last couple of years, and our share price still gets sold back down, its hard when the market dosent understand new products like Ortho-ATI, management are just starting to get a foot in the door through trials / results, marketing and education, but we will need a bigger budget for our next move. I have no doubt in my mind who ever picks up a partnership with Orthocell will be making an absolute killing with the sales of Orthocell product $$$